Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Juergen Schnaubelt

Werner Rall

Thomas Krueger

Rainer Soyka

Guenter Linz

Rolf Schmid

Adil Duran

Svenja Renner

Markus Frank

Carsten Reichel

Joern Merten

Emanuel Stehle

Matthias Eckhardt

Georg Dahmann

Uwe Joerg Ries

Waldemar F Pfrengle

Peter Sieger

Marco Santagostino

Holger Wagner

Nathan K Yee

Xudong Wei

Rogelio Perez Frutos

Nizar Haddad

Fabrice Gallou

Thomas Nicola

Robert Simpson

Gerd Kraemer

Wenjun Tang

Thorsten Pachur

Dirk Kemmer

Joerg Brandenburg

Yibo Xu

Dieter Gutheil

Rolf Herter

Jutta Kroeber

Christian Kulinna

Ludwig Gutschera

Michael Konrad

Thomas Fachinger

Uwe Stertz

Zeno A Leuter

Robert Hagenkoetter

Kai Oliver Donsbach

Michael Schul

Bianca Werner

Robert Schiffers

Hans-Dieter Ecker

Eric Winter

Norbert Birk

Heidelore Heimroth

Armin Proell

Sabrina Kusserow

The present invention relates to compounds of formula I wherein Rdenotes F or CF, Rdenotes H or C-alkyl and Z denotes a leaving group or an optionally substituted or protected hydroxyl group, suitable as intermediates in the synthesis of indanyloxydihydrobenzofuranylacetic acids, which are GPR40 agonists, to a process for preparing these intermediates and to the process for preparing the GPR40 agonists making use of an asymmetric catalytic hydrogenation reaction in the presence of a transition metal catalyst and a chiral auxiliary.

Process and intermediates for preparing GPR40 agonists

The present invention relates to a process for making 2,4-differentiated 5-trifluoromethyl pyrimidines and 2-amino-5-trifluoromethyl-pyrimidine derivatives, which compounds are useful in the preparation of pharmacologically active compounds.

Selective synthesis of functionalized pyrimidines

The invention relates to a method for the stereoselective preparation of a compound of formula (5), optionally in the form of the tautomers thereof, 

Method for stereoselective synthesis of bicyclic heterocyclic compounds

The present invention relates to an improved process for manufacturing dihydropteridinones of general formula (12) as well as intermediates thereof, wherein the groups R, R, R, R, and Rhave the meanings given in the claims and specification.

Process for manufacturing dihydropteridinones and intermediates thereof

An improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.

Process for preparing amino crotonyl compounds

The present invention relates to a process for preparing betamimetics of formula 1, 

Process for the manufacturing of betamimetics

The present invention relates to a process for the manufacture of a specific indolinone derivative and a pharmaceutically acceptable salt thereof, namely 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and its monoethanesulfonate, to new manufacturing steps and to new intermediates of this process.

Process for the manufacture of an indolinone derivative

A process for preparing compounds of the formula (I) in which Rand Rare as defined in the description.

Preparation process

The present invention relates to a method of preparing compounds of general formula I wherein m, n, Rand Rare defined as mentioned hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases.

Process for making certain compounds having B1 antagonistic activity

The present invention relates to a process for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one of formula which is to be found as a structural element in CGRP antagonists which are suitable above all for the oral therapy of migraine. 

3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one

Disclosed is a process for preparing a macrocyclic compound of the formula (I): which is carried out using an intermediate of the formula (II): wherein W, Rthrough R, D, A and Rare as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Process for preparing macrocyclic compounds

The present invention relates to a process for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one of formula which is to be found as a structural element in CGRP-antagonists, which are particularly suitable for the oral treatment of migraine.

Growing community of inventors

Oberhoefen/Warthausen, Germany

Juergen Schnaubelt